WO2023152644 - PHARMACEUTICAL COMPOSITION OF LIFITEGRAST AND LOTEPREDNOL ETABONATE
National phase entry is expected:
Publication Number
WO/2023/152644
Publication Date
17.08.2023
International Application No.
PCT/IB2023/051101
International Filing Date
08.02.2023
Title **
[English]
PHARMACEUTICAL COMPOSITION OF LIFITEGRAST AND LOTEPREDNOL ETABONATE
[French]
COMPOSITION PHARMACEUTIQUE DE LIFITEGRAST ET D'ÉTABONATE DE LOTÉPREDNOL
Applicants **
ORBICULAR PHARMACEUTICAL TECHNOLOGIES PVT. LTD
P. No. 53, ALEAP Industrial Estate, Pragati Nagar, Kukatpally,
Hyderabad-500 090, Telangana, IN
Inventors
PATEL, Hiren
Orbicular Pharmaceutical
Technologies Pvt. Ltd.
P. No. 53,
ALEAP Industrial Estate,
Pragati Nagar,
Kukatpally,
Hyderabad-500 090,
Telangana, IN
Priority Data
202241006646
08.02.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 995 | |
| EPO | Filing, Examination | 6431 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 11301 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to pharmaceutical composition comprising combination of Lifitegrast and Loteprednol etabonate along with one or more pharmaceutically acceptable excipients for the treatment of dry eye disease.[French]
La présente invention concerne une composition pharmaceutique comprenant une combinaison de Lifitegrast et d'étabonate de lotéprednol conjointement avec un ou plusieurs excipients pharmaceutiquement acceptables pour le traitement du syndrome de l’œil sec.